ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2026
[Chinese Expert Consensus on Diagnosis and Treatment of Non-small Cell Lung Cancer with MET Abnormality (2026 Version)].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mesenchymal-epithelial transition factor (MET) gene, located on human chromosome 7, exerts critical regulatory roles in cellular processes including proliferation, migration, invasion, and angiogenesis. As a key driver gene in non-small cell lung cancer (NSCLC), MET abnormalities encompass MET exon 14 (METex14) skipping mutations, gene amplification, protein overexpression, gene fusions, and activating mutations. This consensus, developed by the Lung Cancer Specialty Committee of the Chinese Elderly Health Care Association, updates the 2025 version with several key modifications: elevating the recommendation level for MET amplification and protein overexpression testing, advocating routine testing for all newly diagnosed NSCLC patients and those with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs); standardizing targeted therapy approaches for MET amplification in driver gene-negative settings and following EGFR-TKIs resistance; and subdividing MET protein overexpression-related management into post-EGFR-TKIs resistance and driver gene-negative categories with corresponding treatment protocols, thereby offering more actionable guidance for precise clinical decision-making. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.